Estimates Revisions Clinuvel Pharmaceuticals Limited Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.369 EUR | +9.81% |
|
+14.50% | -14.29% |
| 06-16 | Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade | MT |
| 04-28 | Clinuvel Pharmaceuticals plans level II ADR upgrade and Nasdaq listing as CUVL | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
- Consensus Clinuvel Pharmaceuticals Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
